Analyst Price Targets — WST
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 13, 2026 2:34 pm | Dan Leonard | UBS | $340.00 | $246.60 | TheFly | West Pharmaceutical price target lowered to $340 from $355 at UBS |
| February 13, 2026 1:36 pm | — | Deutsche Bank | $315.00 | $247.49 | TheFly | West Pharmaceutical price target raised to $315 from $310 at Deutsche Bank |
| February 13, 2026 11:23 am | Luke Sergott | Barclays | $265.00 | $243.61 | TheFly | West Pharmaceutical price target lowered to $265 from $325 at Barclays |
| February 10, 2026 2:10 pm | David Windley | Jefferies | $295.00 | $249.97 | TheFly | West Pharmaceutical price target lowered to $295 from $365 at Jefferies |
| February 3, 2026 1:02 pm | Daniel Markowitz | Evercore ISI | $320.00 | $237.88 | TheFly | West Pharmaceutical price target lowered to $320 from $390 at Evercore ISI |
| December 1, 2025 9:26 pm | — | Morgan Stanley | $285.00 | $274.14 | TheFly | West Pharmaceutical initiated with an Equal Weight at Morgan Stanley |
| October 27, 2025 12:39 pm | — | Barclays | $325.00 | $293.62 | TheFly | West Pharmaceutical price target raised to $325 from $275 at Barclays |
| October 24, 2025 12:18 pm | Dan Leonard | UBS | $355.00 | $307.25 | TheFly | West Pharmaceutical price target raised to $355 from $320 at UBS |
| October 24, 2025 11:17 am | Justin Bowers | Deutsche Bank | $345.00 | $304.74 | TheFly | West Pharmaceutical price target raised to $345 from $305 at Deutsche Bank |
| October 23, 2025 3:50 pm | Daniel Markowitz | Evercore ISI | $390.00 | $309.28 | TheFly | West Pharmaceutical price target raised to $390 from $350 at Evercore ISI |
Latest News for WST
WST rides strong HVP demand and GLP-1 expansion, but tariffs, destocking pressures and European facility constraints pose near-term growth risks.
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXTON, Pa., April 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2026 financial results before the market opens on Thursday, April 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Align Technology (ALGN) or West Pharmaceutical Services (WST). But which of these two stocks is more attractive to value investors?
West Pharmaceutical expands Dublin facility to boost injectable therapy capacity and strengthen its end-to-end manufacturing platform.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.